MELBOURNE, Australia and PRINCETON, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ...

The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...

KRAS mutated endothelium promotes the occurrence and development of AVMs through a variety of ways, including promoting EndMT, angiogenesis, VEGF signaling pathway and pericyte loss. KRAS mutation in ...

Researchers have developed a bioinspired conductive hydrogel called PEDOT:sGAGh that can simultaneously handle electrical signals and biochemical cues, letting scientists precisely control whether ...

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...